Imunon shares surge 15.24% intraday as pivotal Phase 3 OVATION 3 trial advances and MRD data reinforce IMNN-001's breakthrough potential in ovarian cancer.

Imunon surged 15.24% intraday after disclosing strong clinical progress in its Phase 3 OVATION 3 trial and positive data from an MRD study. The company highlighted a 13-month median overall survival extension in its Phase 2 trial, with promising long-term outcomes in patients receiving IMNN-001, and emphasized translational data showing macrophage activation and tumor microenvironment remodeling. These advancements, coupled with the potential for a biologics license application filing, underscored investor confidence in the therapy’s transformative potential for ovarian cancer. A concurrent $7 million registered direct offering was also announced to support ongoing trials, but the primary catalyst for the intraday rally was the clinical milestone reinforcing the drug’s promise as a breakthrough immunotherapy.